Purpose: Glioblastoma remains highly lethal with poor prognosis despite surgery, radiation, and chemotherapy. Gene therapy is a promising alternative, but viral vectors carry safety risks. Non-viral polymeric nanoparticles are safer but have historically shown poor in vivo efficacy. A biodegradable poly(beta-amino ester) (PBAE) nanoparticle system was developed to deliver a suicide gene to malignant glioma and improve survival.
Hypothesis: If PBAE nanoparticles are optimized for DNA delivery to glioma cells and administered intratumorally via convection-enhanced delivery (CED), then delivery of herpes simplex virus type I thymidine kinase (HSVtk) combined with systemic ganciclovir (GCV) will produce effective cancer cell killing in vitro and significantly extend survival in a rat malignant glioma model.
Aims: Synthesize and screen a PBAE polymer library for DNA delivery to 9L and F98 rat glioma cells. - Identify lead nanoparticle formulations with high transfection and low cytotoxicity. - Characterize the lead PBAE/DNA nanoparticle size, zeta potential, and lyophilization stability. - Evaluate HSVtk/GCV suicide gene therapy in vitro. - Assess in vivo safety, intratumoral distribution, and transfection after CED infusion. - Test therapeutic efficacy and survival benefit in a 9L gliosarcoma rat model.
Delivery system:
Component: Polymer class; Details: Biodegradable poly(beta-amino ester)s (PBAEs)
Component: Lead polymer; Details: 447: 1-(3-aminopropyl)-4-methylpiperazine end-modified poly(1,4-butanediol diacrylate-co-4-amino-1-butanol)
Component: Nanoparticle type; Details: Polymeric DNA nanoparticles
Component: Payload; Details: Plasmid DNA: GFP reporter, HSVtk suicide gene, Cy5-labeled GFP
Component: Size / zeta; Details: 447 30 w/w: 138 ± 4 nm; zeta potential 13 ± 1 mV
Component: Targeting ligand; Details: None
Component: Administration; Details: Intratumoral convection-enhanced delivery (CED); bolus injection for comparison
Component: Key feature; Details: Biodegradable, lyophilizable, safe for brain delivery; wide tumor distribution with CED
Approach: In vitro: 9L rat gliosarcoma and F98 rat glioma cell lines; GFP transfection screen; MTS cytotoxicity; HSVtk/GCV killing assay with GCV 0, 5, 50 µg/mL. - In vivo safety: Healthy wild-type F344 rats and 9L tumor-bearing rats; PBAE/GFP nanoparticles infused via CED; histopathology at day 3 and day 60; GCV tolerance. - In vivo distribution/transfection: 9L tumor-bearing rats; Cy5-labeled GFP DNA nanoparticles via CED vs bolus; immunofluorescence 24 h post-infusion. - In vivo efficacy: 9L tumor-bearing F344 rats randomized to: untreated control (n=16); GCV alone (n=8); NP-GFP + GCV (n=8); HSVtk DNA + GCV (n=8); NP-HSVtk + GCV (n=8). GCV 50 mg/kg twice daily days 4–13; single CED infusion day 6. - Disease context: Malignant glioma/gliosarcoma; no human studies.
Key methods: Polymer/nanoparticle characterization: GPC, ¹H NMR, DLS, zeta potential, TEM. - Transfection: Flow cytometry for GFP-positive cells; fluorescence microscopy. - Cytotoxicity: MTS assay. - HSVtk/GCV killing: PI/DAPI staining and cell counting. - In vivo safety: Histopathology of brain tissue. - Distribution/transfection: Immunofluorescence for GFP and Cy5; confocal microscopy. - Survival: Kaplan–Meier plots; log-rank (Mantel–Cox) test. - Statistics: One-way ANOVA with Dunnett’s post-test; two-tailed t-tests; p < 0.05.
Key results: In vitro transfection: Ten PBAE nanoparticle formulations achieved >50% transfection with <20% toxicity in 9L cells; eight formulations in F98 cells. Three formulations were superior to Lipofectamine 2000 in 9L; fifteen in F98. - Lead formulation: 447 at 30 w/w led to 52 ± 1% transfection in 9L and 37 ± 4% in F98. Nanoparticles were 138 ± 4 nm with zeta potential 13 ± 1 mV. - HSVtk/GCV killing: In both 9L and F98 cells, HSVtk nanoparticles + GCV caused approximately 100% cancer cell death at 5 and 50 µg/mL GCV; GFP-transfected cells remained viable. - Lyophilization: No significant change in size, zeta potential, or transfection efficacy after lyophilization. - In vivo safety: No neurotoxicity or histopathological damage in healthy or tumor-bearing rats; 50 mg/kg GCV twice daily was tolerated. - CED distribution: CED led to transfection throughout the entire tumor mass; bolus injection transfected mainly near the needle tract. CED increased normalized GFP fluorescence by 36% vs bolus (15.8 ± 0.1 vs 11.6 ± 0.2 RFU, p < 0.0001). - Survival: PBAE/HSVtk + GCV significantly extended survival vs untreated control (p = 0.0012), GCV alone (p = 0.0102), NP-GFP + GCV (p = 0.027), and HSVtk DNA + GCV (p = 0.027).
Interpretation: The authors claim this is the first demonstration of a successful non-viral nanomedicine for HSVtk/GCV suicide gene therapy of brain cancer. Biodegradable PBAE nanoparticles enabled effective DNA delivery, wide tumor distribution via CED, and significant survival benefit in a malignant glioma model. The approach is proposed as a promising alternative to viral gene therapy for glioblastoma.
Limitations: Just Accepted manuscript: Final peer-reviewed version may differ. - Animal model only: Rat 9L gliosarcoma; no human or large-animal validation. - Single in vivo tumor model: Efficacy tested only in 9L, not F98 or other glioma models. - Small sample size: n = 8 per treatment group; control n = 16. - No median survival numbers reported in text; only survival curves and p-values. - No direct comparison to viral vectors. - No immune response or long-term toxicity data. - Invasive delivery: Requires CED or intratumoral injection; not systemic delivery. - No targeting ligand: Distribution relies on local administration. - No dose–response optimization for PBAE/HSVtk nanoparticles. - No evaluation of repeated dosing or combination with standard therapies.
